Search the Newsreel

Earnings Flash (JAN) Janus Living, Inc. Reports Q2 Revenue $216.5M, vs. FactSet Est of $215.2M

Janus International Group (JBI) Expected to Release Quarterly Earnings on Tuesday

Janus International Group (JBI) is scheduled to release its Q2 2026 earnings before market open on Tuesday, August 11th. Analysts anticipate earnings of $0.13 per share and revenue around $238.8 million. The company's stock recently traded at $5.54, with institutional investors holding a significant …

Ajanta Pharma Share Price Falls 2.17% After Q1 Results

Ajanta Pharma uploads Q1FY27 earnings call transcript

Ajanta Pharma profit rises 31% to ₹334 cr in Q1FY27 on US surge

Results: Ajanta Pharma Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Janus International Group, Inc. (NYSE:JBI) Given Consensus Rating of "Hold" by Brokerages

Janus International Group (NYSE:JBI) has received a consensus "Hold" rating from brokerages, with an average 12-month price target of $8.33. The stock recently opened at $5.14, trading significantly below its 52-week high, and is down 4.2%. Despite a 5.8% year-over-year revenue increase to $222.7 …

Form 4 Janux Therapeutics Inc For: 31 July By Investing.com

This article announces the filing of a Form 4 for Janux Therapeutics Inc. for the period ending July 31. It provides no further details beyond this announcement and includes general market data and related news. The Form 4 filing is a mandatory SEC document …

Vanguard Capital Management (JBI) discloses 6.89M-share passive stake in Janus

Vanguard Capital Management LLC and its affiliates have reported a passive ownership of 6,887,889 shares in Janus International Group Inc., constituting 5.05% of the company's common stock. This Schedule 13G filing indicates that Vanguard exercises sole voting power over 1,021,614 shares and sole dispositive …

Janux Therapeutics Inc (JANX) Institutional Confidence

Janux Therapeutics Inc (JANX) has an institutional shareholding score of 10.00, ranking 1st in its industry. The institutional shareholding proportion increased by 0.64% quarter-over-quarter, reaching 110.21%. Steven Cohen is the largest institutional shareholder, though his holdings decreased by 62.25%.

Janux Therapeutics Inc (JANX) Financial Health: Profitability & Balance Sheet Analysis

Janux Therapeutics Inc (JANX) currently holds a financial score of 7.85, ranking 76th out of 384 companies in the Biotechnology & Medical Research industry. The company's financial status is deemed stable, while its operating efficiency is considered average. Key financial metrics such as total …

Ajanta Pharma Q1 FY27 slides: 25% revenue surge, US sales jump 57%

Janux Therapeutics Inc (JANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Janux Therapeutics Inc (JANX), detailing its price momentum score of 3.51 within the Biotechnology & Medical Research industry. It identifies current support at $14.46 and resistance at $16.80, suggesting suitability for range-bound swing trading. The analysis also …

Ajanta Pharma's India, US Momentum Drives Q1 Beat; Jefferies Sees More Upside Ahead

Ajanta Pharma shares fall 2.06%, trading at Rs 3,365.60

Understanding Momentum Shifts in (JANX)

An analysis of Janux Therapeutics Inc. (NASDAQ: JANX) indicates weak sentiment across all time horizons, supporting a short bias. The article identifies a mid-channel oscillation pattern and highlights an exceptional 99.0:1 risk-reward short setup targeting a 29.8% downside. AI-generated trading strategies are provided for …

Janux Therapeutics, Inc. Revenue Breakdown – NASDAQ:JANX

Janux Therapeutics, Inc. (NASDAQ:JANX) generated $10.00 million USD in revenue last year, primarily from its Novel Immunotherapies segment, which also contributed $10.00 million USD in revenue. The United States was its largest geographical contributor, also accounting for $10.00 million USD in revenue in the …

Earnings call transcript: Ajanta Pharma posts strong Q1 2026 growth, shares rise

Janux Therapeutics Inc (JANX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Janux Therapeutics Inc (JANX), noting its current valuation score of 7.63, which ranks it 208 out of 384 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -8.12, comparing it to recent …

Janux Therapeutics (JANX) Projected to Post Quarterly Earnings on Thursday

AJANTPHARM: Q1 FY27 delivered 25% revenue and 31% net profit growth, led by branded and US generics

AJANTPHARM: Q1 revenue up 25% YoY, profit after tax up 31%, with strong growth in India, Africa, and U.S

Ajanta Pharma Q1 Result: Net Profit Jumps 31%, Revenue At Rs 1,626 Crore; Dividend Announced

PT Metropolitan Kentjana Tbk Reports Earnings Results for the Half Year Ended June 30, 2026

Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides information regarding Janux Therapeutics Inc (JANX) stock, focusing on its dividend and stock split history. It states that the company has not distributed any dividends over the past five years. Key financial data like market cap and current stock price are …

JANX|Janux Therapeutics Inc|Price:15.635|Chg%:+0.305

Janux Therapeutics Inc (JANX) has a TradingKey Stock Score of 6.70/10, indicating relatively healthy fundamentals and high growth potential, though its valuation is only considered fair. The company specializes in developing tumor-activated immunotherapies for cancer, with significant revenue and profit growth. Analysts have a …

Janux Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

Janux Therapeutics Inc. (JANX) is a clinical-stage biopharmaceutical company focused on developing tumor-activated immunotherapies for cancer using its TRACTr and TRACIr platforms. The company's clinical candidates, JANX007 and JANX008, target prostate cancer and various solid tumors respectively. The article provides an overview of the …

Janux Therapeutics Inc (JANX) Income Statement

This article presents the quarterly and annual income statements for Janux Therapeutics Inc. (JANX), detailing revenue, operating expenses, research and development costs, and net income figures. It provides insights into the company's financial performance and efficiency over various fiscal periods, alongside a FAQ section …

JBI|Janus International Group Inc|Price:5.050|Chg%:-0.320

Janux Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Barrett Ronald W

This article is a statement of changes in beneficial ownership of securities for Director Ronald W. Barrett of Janux Therapeutics. It is identified as a Form 4 filing, which indicates a required disclosure of stock transactions by company insiders. The full content is described …

Janus Living Reaches Analyst Target Price

In recent trading, shares of Janus Living Inc (Symbol: JAN) have crossed above the average analyst 12-month target price of $30.50, changing hands for $30.65/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade …

Janus International schedules Aug. 11 webcast on Q2 results

Janus International Group (NYSE: JBI) announced it will release its second quarter 2026 financial results on August 11, 2026, before market open. The company will also host a conference call and webcast on the same day at 10:00 a.m. ET to discuss the results …

Small-, mid-cap banks shine: Jana Small, South Indian Bank surge up to 7%

Jana Small Finance Bank reports FY25 RBI divergence; says no impact on FY27 earnings

Jana Small Finance Bank Share Price Forecast to 2030

Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street